PharmAthene said the combined company will have four clinical-stage products, giving it the diversified portfolio desired by management.
The FDA has lifted the clinical hold on PharmAthene's anthrax vaccine candidate, SparVax.
The FDA froze biodefense company PharmAthene's anthrax vaccine, SparVax rPA, sending shares tumbling 17% to $1.21 in recent premarket trading, The Wall Street Journal reports.
PharmaThene, supported with federal funding, is developing an anti-bioterrorism anthrax vaccine, SparVax, and is planning further Phase II trials for the second half of 2012.
Emergent BioSolutions' monopoly on approved anthrax vaccines was worth a new federal contract worth up to $404 million for a fresh stockpile. Emergent will supply 14.5 million doses of its vaccine
PharmAthene is making a bid to develop a next-gen anthrax vaccine that can qualify for a $400 million government contract. The small Maryland developer is paying up to $40 million for a pair of